Form 4 for NTLA Intellia Therapeutics, Inc.
Accepted 2022-03-03 00:00:00 ET · period of report 2022-01-01 · accession 0001209191-22-015976 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-03-03 | 2022-03-01 | NTLA | Sepp-Lorenzino Laura | EVP, CSO | A - Grant | $0.00 | +13.8K | 18.6K | +287% | $0 |
| D | 2022-03-03 | 2022-01-01 | NTLA | Sepp-Lorenzino Laura | EVP, CSO | S - Sale+OE | $112.25 | -1,148 | 4,815 | -19% | -$128.9K |
| D | 2022-03-03 | 2022-01-01 | NTLA | Sepp-Lorenzino Laura | EVP, CSO | M - OptEx | — | +3,500 | 5,963 | +142% | — |
| D | 2022-03-03 | 2022-01-01 | NTLA | Sepp-Lorenzino Laura | EVP, CSO | M - OptEx | $0.00 | -3,500 | 10.5K | -25% | $0 |
| D | 2022-03-03 | 2022-03-01 | NTLA | Sepp-Lorenzino Laura | EVP, CSO | A - Grant | $0.00 | +13.8K | 13.8K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-03-01 | A | A | 13,816 | $0.00 | 18,631 | D | — | — | (F4) Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit. |
| 2 | Common | Common Stock | 2022-01-01 | S | D | 1,148 | $112.25 | 4,815 | D | — | — | |
| 3 | Common | Common Stock | 2022-01-01 | M | A | 3,500 | — | 5,963 | D | — | — | (F1) Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. (F2) Includes 72 shares acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan on December 31, 2021. |
| 4 | Derivative | Restricted Stock Unit | 2022-01-01 | M | D | 3,500 | $0.00 | 10,500 | D | — · 2022-01-01 to 2031-03-02 | 3,500 Common Stock | (F1) Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. (F5) On March 3, 2021, the reporting person was granted 14,000 RSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments thereafter. |
| 5 | Derivative | Stock Option (right to buy) | 2022-03-01 | A | A | 13,816 | $0.00 | 13,816 | D | $79.85 · — to 2032-02-28 | 13,816 Common Stock | (F6) This option was granted on March 1, 2022 with respect to shares of Common Stock, with 33% vesting on January 1, 2023 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter. |